Rep. Lisa C. McClain Purchases Shares of Novartis AG (NYSE:NVS)

Representative Lisa C. McClain (R-Michigan) recently bought shares of Novartis AG (NYSE:NVS). In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Novartis stock on June 11th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Autoliv (NYSE:ALV) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Applied Materials (NASDAQ:AMAT) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of Arthur J. Gallagher & Co. (NYSE:AJG) on 8/4/2025.
• Sold $1,001 – $15,000 in shares of SAP (NYSE:SAP) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of XPO (NYSE:XPO) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of Lithia Motors (NYSE:LAD) on 7/22/2025.
• Sold $1,001 – $15,000 in shares of Sanofi (NASDAQ:SNY) on 7/22/2025.
• Sold $1,001 – $15,000 in shares of Waters (NYSE:WAT) on 7/22/2025.
• Purchased $1,001 – $15,000 in shares of Group 1 Automotive (NYSE:GPI) on 7/22/2025.

Novartis Trading Up 0.1%

NYSE:NVS opened at $126.9410 on Friday. The company has a current ratio of 0.82, a quick ratio of 0.62 and a debt-to-equity ratio of 0.53. The stock has a market capitalization of $268.15 billion, a PE ratio of 18.48, a price-to-earnings-growth ratio of 1.78 and a beta of 0.62. The firm’s 50 day moving average is $119.37 and its 200 day moving average is $113.73. Novartis AG has a 12 month low of $96.06 and a 12 month high of $128.03.

Novartis (NYSE:NVS) last posted its quarterly earnings results on Thursday, July 17th. The company reported $2.42 EPS for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. The company had revenue of $14.05 billion for the quarter, compared to analysts’ expectations of $13.94 billion. Novartis had a net margin of 25.64% and a return on equity of 41.08%. Novartis’s revenue was up 12.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.97 EPS. Sell-side analysts expect that Novartis AG will post 8.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on NVS. Morgan Stanley raised shares of Novartis from an “underweight” rating to an “equal weight” rating and set a $123.00 price target on the stock in a report on Friday, August 8th. Wall Street Zen cut shares of Novartis from a “strong-buy” rating to a “buy” rating in a report on Friday. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, seven have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Novartis presently has a consensus rating of “Hold” and an average price target of $123.50.

Institutional Investors Weigh In On Novartis

Hedge funds and other institutional investors have recently bought and sold shares of the business. Wealthcare Advisory Partners LLC raised its holdings in Novartis by 9.0% during the 1st quarter. Wealthcare Advisory Partners LLC now owns 3,041 shares of the company’s stock valued at $339,000 after acquiring an additional 252 shares during the period. Brighton Jones LLC increased its holdings in shares of Novartis by 76.5% in the fourth quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock worth $599,000 after purchasing an additional 2,666 shares during the period. Rhumbline Advisers increased its holdings in shares of Novartis by 11.1% in the first quarter. Rhumbline Advisers now owns 38,600 shares of the company’s stock worth $4,303,000 after purchasing an additional 3,846 shares during the period. Spire Wealth Management increased its holdings in shares of Novartis by 17.2% in the first quarter. Spire Wealth Management now owns 3,032 shares of the company’s stock worth $338,000 after purchasing an additional 446 shares during the period. Finally, Versant Capital Management Inc increased its holdings in shares of Novartis by 856.3% in the first quarter. Versant Capital Management Inc now owns 7,507 shares of the company’s stock worth $837,000 after purchasing an additional 6,722 shares during the period. Institutional investors own 13.12% of the company’s stock.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.